OTLKW - Outlook Therapeutics, Inc. - Se

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.1450
0.0000 (0.00%)
At close: 2:01PM EDT
Stock chart is not supported by your current browser
Previous Close0.1450
Open0.1127
Bid0.1230 x 2900
Ask0.2500 x 1400
Day's Range0.1127 - 0.1550
52 Week Range0.1127 - 0.1550
Volume10
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Outlook Therapeutics Announces Reverse Stock Split

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today that its Board of Directors has approved a 1-for-8 reverse stock split of the Company’s common stock, which became effective this morning immediately upon the filing by the Company of a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware. Beginning on March 18, 2019, the Company’s common stock will trade on the Nasdaq Capital Market on a reverse stock split-adjusted basis under the new CUSIP number 69012T206.

  • GlobeNewswire

    Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements

    CRANBURY, N.J., March 05, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today that the Company received formal notice from The Nasdaq Stock Market.

  • GlobeNewswire

    Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today the submission of its Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for ONS-5010. ONS-5010 is an innovative monoclonal antibody (mAb) therapeutic product candidate being developed for wet age related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). Once effective, the IND will allow the Company to begin enrolling patients in the U.S. portion of its ONS-5010-002 Phase 3 clinical trial in patients with wet AMD.

  • GlobeNewswire

    Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019

    CRANBURY, N.J., Feb. 14, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its first fiscal quarter.

  • GlobeNewswire

    Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement

    CRANBURY, N.J., Feb. 01, 2019 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the final tranche (of four) of its $20.0 million.

  • GlobeNewswire

    Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants

    Outlook Therapeutics, Inc. (Nasdaq: OTLK, OTLKW) (the “Company”) today announced that its publicly traded Series A warrants (OTLKW) have been amended to lower the exercise price to $1.50 per share and further extend the maturity until 5:00 p.m. New York City time on February 18, 2022. The Series A warrants were issued as part of the units in its May 2016 initial public offering and in a concurrent private placement and were exercisable for shares of its common stock at an initial exercise price of $6.60 per share. The Series A warrants, as previously extended, would have expired at 5:00 p.m. New York City time on the earlier to occur of (a) the date that was twenty (20) business days after the date on which the closing sales price of the common stock was greater than or equal to $7.25 per share and (b) February 18, 2019.

  • GlobeNewswire

    Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) today announced that it closed on the third tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company’s strategic business partner and largest investor, receiving $4.0 million of cash proceeds in exchange for the issuance of 4,288,624 shares of common stock at $0.9327 per share.  The Company has received $16.0 million to date from the sale of its common stock to BioLexis under this private placement, which was previously announced on November 6, 2018.  The remaining $4.0 million will be funded on February 1, 2019, subject to achieving certain funding milestones as set forth in the purchase agreement. The Company intends to use the net proceeds from the private placement primarily for clinical trials for its lead product candidate, ONS-5010, and for working capital and general corporate purposes, including agreed repayments on its senior secured notes.

  • GlobeNewswire

    Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018

    CRANBURY, N.J., Dec. 18, 2018 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its fiscal year ended.